Quick Comparison
| Thymulin | Vilon | |
|---|---|---|
| Half-Life | 1-2 hours | 0.5-1 hours |
| Typical Dosage | Research: 1-5 mg subcutaneous once daily. Anti-aging protocols: 1 mg subcutaneous once daily for 10-20 day courses. Zinc supplementation (15-30 mg zinc daily) recommended for full biological activity. Courses repeated 2-3 times yearly. | Oral/sublingual: 10-20 mg once daily. Injectable: 0.5-5 mg subcutaneous once daily. Typical course: 10-15 days, repeated every 3-6 months. |
| Administration | Subcutaneous injection | Oral, sublingual, or subcutaneous injection |
| Research Papers | 11 papers | 4 papers |
| Categories |
Mechanism of Action
Thymulin
Thymulin (also known as facteur thymique sérique, FTS) is a nonapeptide (Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) that is unique among thymic hormones in requiring a zinc ion for biological activity. The zinc ion is coordinated by the asparagine (position 9), serine (position 4), and the N-terminal glutamic acid, creating a metallopeptide complex where the zinc is essential for the correct three-dimensional conformation needed for receptor binding. Without zinc, thymulin is biologically inactive — this zinc dependency has important implications for immune function in zinc-deficient individuals.
Thymulin is produced exclusively by thymic epithelial cells and is the only thymic hormone that is truly thymus-specific — its serum levels become undetectable after thymectomy (surgical thymus removal). It binds to high-affinity receptors on T-cell precursors (thymocytes) and mature T cells, promoting several key aspects of T-cell biology. It induces the expression of T-cell differentiation markers (CD2, CD3, CD4, CD8), driving immature thymocytes through the stages of T-cell maturation. It enhances the cytotoxic function of CD8+ T cells and the helper function of CD4+ T cells. It modulates the balance between T-helper and T-suppressor (regulatory) cell populations, promoting appropriate immune regulation.
Thymulin also modulates cytokine production — it promotes IL-2 secretion (essential for T-cell proliferation and the generation of effector T cells), enhances IFN-γ production (important for Th1 cellular immunity), and influences the balance of pro-inflammatory versus anti-inflammatory cytokines. Serum thymulin levels peak around puberty and decline progressively with age, becoming virtually undetectable by age 60 — mirroring the age-related involution of the thymus gland. This decline correlates closely with immunosenescence markers: reduced naive T-cell output, skewed CD4/CD8 ratios, impaired vaccine responses, and increased susceptibility to infections and cancer. Zinc supplementation alone can partially restore thymulin activity in zinc-deficient elderly individuals, highlighting the clinical importance of the zinc-thymulin interaction.
Vilon
Vilon (Lys-Glu) is a synthetic dipeptide bioregulator developed as part of the Khavinson peptide bioregulator program, designed to mimic the immune-regulatory effects of thymic peptides in the shortest possible amino acid sequence. As a dipeptide, it is one of the smallest molecules proposed to have specific gene-regulatory activity — which is both its appeal (simplicity, stability, oral bioavailability) and the source of scientific skepticism (whether a two-amino-acid molecule can have specific transcriptional effects).
Vilon is proposed to regulate thymic function and T-cell immunity through the peptide bioregulator mechanism: penetrating cell membranes, entering the nucleus, and interacting with specific DNA sequences in immune-related gene promoters. The reported effects include enhanced T-cell differentiation from thymic precursors, improved balance between CD4+ helper and CD8+ cytotoxic T cell populations, and modulation of cytokine production toward a more balanced Th1/Th2 immune profile.
Preclinical and clinical studies from the Khavinson group have reported that Vilon treatment enhances immune surveillance (the ability of the immune system to detect and eliminate abnormal cells), improves vaccine responsiveness in elderly subjects, and partially reverses age-related immunosenescence markers. In combination with Epithalon (another Khavinson bioregulator targeting telomerase and the pineal gland), Vilon was reported to reduce mortality in a long-term follow-up study of elderly subjects in St. Petersburg. The proposed mechanism for immune enhancement involves restoration of thymic peptide signaling that declines with age-related thymic involution, essentially providing a minimal molecular signal that tells immune progenitor cells to differentiate and mature. As with all Khavinson bioregulators, independent validation through Western clinical trial standards is still needed.
Risks & Safety
Thymulin
Common
injection site reactions, mild fatigue.
Serious
very limited human clinical data for supplemental use, may overstimulate immune system in autoimmune conditions.
Rare
allergic reactions.
Vilon
Common
mild injection site reactions, temporary fatigue.
Serious
very limited Western safety data, may overstimulate immune system in autoimmune conditions, no long-term data on repeated use.
Rare
allergic reactions.
Full Profiles
Thymulin →
A 9-amino-acid peptide naturally produced by the thymus gland that requires zinc to work properly. Distinct from Thymalin (which is a thymic extract mixture). Plays a central role in T-cell development, immune system regulation, and the zinc-thymulin axis that declines with aging. Thymulin levels decrease as the thymus shrinks with age, contributing to immune decline.
Vilon →
A synthetic two-amino-acid peptide (Lys-Glu) designed to support the thymus gland and immune system. Studied for immune modulation, thymic rejuvenation, and anti-aging. Part of the Khavinson peptide bioregulator family alongside Thymalin, Epithalon, and Cortexin. Designed to support T-cell development and restore age-related immune decline.